CureVac
CureVac

CureVac

DR66Ahrefs DR: 66/100. Above median. Measured by Ahrefs. Median 44.Agent38Agent Readiness: 38/100. Below median. Measured by StartupHub.ai. Median 41.Speed84Site Speed: 84/100. Top 25%. Measured by Google PageSpeed. Median 62.

Biopharmaceutical company developing mRNA-based vaccines and therapeutics for infectious diseases and cancer.

Website
2000ActiveTübingen, Germany

About

CureVac is a biopharmaceutical company focused on developing and commercializing novel mRNA-based vaccines and therapeutics. Their technology platform enables the development of treatments for a range of diseases, including infectious diseases and cancer, by leveraging the body's own cells to produce therapeutic proteins.

Key facts

At-a-glance profile data

Website
curevac.com
Headquarters
Tübingen, Germany
Founded
2000
Total funding
$2.1B (IPO)
Business model
B2B

Funding rounds

Funding rounds raised by CureVac
DateRoundAmountLead investors
18 Aug 2020IPO$1.3B-
1 Jun 2020Series B$620M-
1 Jan 2017Series A$110M-

Tech stack

Detected on curevac.com, last scanned 18 Sept 2026. Run your own scan

Hosting
Hetzner
Email provider
Microsoft 365
Add first review

Frequently asked

How much funding has CureVac raised?

CureVac has raised a total of $2.1B in funding. The most recent round on record is IPO.